HPV16-E7 Expression Causes Fluorodeoxyuridine-mediated Radiosensitization in SW620 Human Colon Cancer Cells

Neoplasia

Volumn 1, Issue 2, 1999, Pages 177-182

  Axelson, Michael D ^a   Davis, Mary A ^a   Ethier, Stephen P ^a   Lawrence, Theodore S ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE   (United States)

Author keywords

Cell cycle; Fluoropyrimidines; HPV16 E7; Radiosensitization

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CYCLIN DEPENDENT KINASE; CYCLIN E DEPENDENT KINASE; CYCLIN E-DEPENDENT KINASE; FLOXURIDINE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CULTURE; CELL CYCLE S PHASE; CELL SURVIVAL; COLON TUMOR; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; RADIATION EXPOSURE; RADIATION RESPONSE; RETROVIRUS; TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLOW CYTOMETRY; FLOXURIDINE; HUMANS; IMMUNOBLOTTING; ONCOGENE PROTEINS, VIRAL; RETROVIRIDAE; S PHASE; THYMIDYLATE SYNTHASE; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033139793     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900012     Document Type: Article

References (32)

1. Pu T, Robertson JM, and Lawrence TS (1995). Current status of radiation sensitization by fluorinated pyrimidines. Oncology 9, 707-735.
2. McGinn CJ, and Kinsella TJ (1992). The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 19, 21-28.
3. Lawrence TS, Maybaum J, and Ensminger WD (1994). Infusional fluoropyrimidines as radiation sensitizers: Clinical implications of laboratory findings. Infusional Chemotherapy 4, 120-123.
4. Lawrence TS, Davis MA, Tang H-Y, and Maybaum J (1996). Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S Phase progression. Int J Radiat Biol 70, 273-280.
5. Davis MA, Tang H-Y, Maybaum J, and Lawrence TS (1995). Dependence of fluorodeoxyuridine-mediated radiosensitization on S Phase progression. Int J Radiat Biol 67, 509-512.
6. Lawrence TS, Davis MA, and Loney TL (1996). Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 56, 3203-3206.
7. Boyer SN, Wazer DE, and Band V (1996). E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56, 4620-4624.
8. Wazer DE, Liu XL, Chu Q, Gao Q, and Band V (1995). Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci USA 92, 3687-3691.
9. Lawrence TS, Normolle DP, Davis MA, and Maybaum J (1993). The use of biphasic linear ramped pulsed field gel electrophoresis to quantify DNA damage based on fragment size distribution. Int J Radiat Oncol Biol Phys 27, 659-663.
10. Fertil B, Dertinger H, Courdi A, and Malaise EP (1984). Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radial Res 99, 73-84.
11. Hoy CA, Seamer LC, and Schimke RT (1989). Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of the BrdUrd/DNA histogram. Cytometry 10, 718-725.
12. Kung AL, Sherwood SW, and Schimke RT (1993). Differences in the regulation of protein synthesis, Cyclin B accumulation, and cellular growth in response to the inhibition of DNA synthesis in Chinese hamster ovary and HeLa S3 cells. J Biol Chem 268, 23072-23079.
13. Maley F, Pedersen-Lane J, and Changchien L-M (1995). Complete restoration of activity to inactive mutants of Escherichia coli thymidylate synthase: Evidence the E. coli thymidylate synthase is a half-the-sites activity enzyme. Biochemistry 34, 1469-1479.
14. Dulic V, Lees E, and Reed SI (1992). Association of human Cyclin E with a periodic G1-S phase protein kinase. Science 257, 1958-1961.
15. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl G, and Bertino J (1995). Lack of functional retinoblastoma protein mediated increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 92, 10436-10440.
16. Demers GW, Foster SA, Halbert CL, and Galloway DA (1994). Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by HPV 16 E7. Proc Natl Acad Sci USA 91, 4382-4386.
17. Slebos RJC, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, and Cho KR (1994). p53-dependent G1 arrest involves pRB-related proteins and is disrupted by HPV 16 E7 oncoprotein. Proc Natl Acad Sci USA 91, 5320-5324.
18. Kuerbitz SJ, Plunkett BS, Walsh WV, and Kastan MB (1992). Wild type p53 is a cell cycle check point determinant following irradiation. Proc Natl Acad Sci USA 89, 7491-7495.
19. Kastan MB, Onyekwere O, Sidransky D, Volgestein B, and Craig RW (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304-6311.
20. Nabeya Y, Loganzo FJ, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell Ml, Altorki NK, Kelsen DP, and Albino AP (1995). The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 64, 37-46.
21. Sun X, Shimizu H, and Yamamoto K (1995). Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol Cell Biol 15, 4489-4496.
22. Matsui S, Arrendondo A, Wrzosek C, and Rustum YM (1996). DNA Damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res 56, 4715-4723.
23. Yin M, Voigt W, Panadero A, Vanhoefer U, Frank C, Pajovic S, Azizkhan J, and Rustum Y (1997). p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Mol Pharmacol 51, 630-636.
24. Sklower S, Jenkins E, Anderson M, Chan C, and Brown W (1986). Variability of TS activity in whole blood cultures treated with FUdR. Am J Med Genet 23, 483-490.
25. Cantu E, Nassbaum R, Airhart S, and Ledbetter D (1985). Fragile (X) expression induced by FUdR is transient and inversely related to levels of TS activity. Am J Hum Genet 37, 947-955.
26. Naida JD, Davis MA, and Lawrence TS (1998). The effect of activation of wild type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys 41, 675-680.
27. Jones DL, and Munger K (1997). Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71, 2905-2912.
28. Hickman ES, Bates S, and Vousden KH (1997). Perturbation of the p53 response by human papillomavirus type 16 E7. J Virol 71, 3710-3718.
29. Bunch RT, and Eastman A (1997). 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 8, 779-788.
30. Painter RB, and Young BR (1980). Radiosensitivity in ataxia-telangiectasia: A new explanation. Proc Natl Acad Sci USA 77, 7315-7317.
31. Lavin MF, and Shiloh Y (1996). The genetic defect in ataxia-telangiectasia. Annu Hev Immunol 15, 177-202.
32. Price BD, and Youmell MB (1996). The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 56, 246-250.